Overall response rate (CR, CRi, PR, and HI) by baseline characteristics | Download Scientific Diagram
Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy - ScienceDirect
Auditory and sexual preferences for a father's song can co-emerge in female Bengalese finches | PLOS ONE
I never lost hope” – One Man's Journey with Advanced Kidney Cancer
Observational Study Protocol CA209-7MA
Relationship Between Progression‐Free Survival, Objective Response Rate, and Overall Survival in Clinical Trials of PD‐1/PD‐L1 Immune Checkpoint Blockade: A Meta‐Analysis - Ye - 2020 - Clinical Pharmacology & Therapeutics - Wiley Online
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
The overall response rate | Download Table
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer | Scientific Reports
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer - touchONCOLOGY
IKCS 2022: Real-world Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma | NEJM
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Best Overall Response and Time to Response | Download Table
Best Overall Response Rate to Treatment | Download Table
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text
Response Rate Definition | The Online Advertising Guide
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer | NEJM
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text